Navigation Links
Hoya Announces Second Quarter and First Half Financial Results for FY2008
Date:11/10/2008

TOKYO, November 10 /PRNewswire-FirstCall/ -- HOYA Corporation today announced financial results for the second quarter ended September 30, 2008. Net sales were 128.3 billion yen for the quarter, representing an increase of 27.1% from 100.9 billion yen in the second quarter of 2007 mainly reflecting the additional results of PENTAX included in the scope of consolidation during the previous fiscal year.

Operating income was 20.6 billion yen, a 23.2% decrease compared with 26.8 billion yen in the second quarter of 2007, due mainly to order decrease and the drop in the product price in global economic downturn. Net income for the second quarter was 19.1 billion yen, a 9.0% decrease compared with 21.0 billion yen in the same period of 2007. Earnings per share for the quarter were 44.21 yen compared with 48.64 yen in the second quarter of 2007.

For the first six months ending September 30, 2008, net sales were 258.5 billion yen, a 30.1% growth compared with 198.7 billion yen in the same period of 2007. Operating income was 42.4 billion yen, a 14.2% decrease compared with 49.4 billion yen in the first half of 2007, while net income was 40.3 billion yen, a 5.8% increase compared with 38.1 billion yen in the same period of 2007. Earnings per share were 93.18 yen compared with 88.25 yen in the first half of 2007.

"Shrinkage of the semiconductor market and severe price competition in overall business fields continues to have a negative impact on our second quarter 2008," said Hiroshi Hamada, chief operating officer of HOYA. "The market will continue to be weak, however, we will promote expansion of our growth areas including eyeglass business, endoscopic system and contact lens retail business."

The full quarterly report is available in "Financial Statement" page in HOYA website Investor Relations section at: http://www.hoya.co.jp/english/

*Results are preliminary and unaudited.

*The yen amounts shown therein are rounded down to the nearest 100 million.

About Hoya Corporation

Hoya Corporation is a global technology company based in Tokyo, Japan, and the leading supplier of innovative and indispensable high-tech products and services based upon its advanced optics technologies. Hoya is active in four fields of business: Information Technology makes mask blanks and photomasks for the semiconductor devices and LCD panels, optical lenses for digital cameras, and glass memory disks for HDDs. The Eye Care provides eyeglasses, operates retail shops for contact lenses, and makes intraocular lenses for cataract surgery. The Life Care provides endoscopic system. The Imaging produces SLR/compact digital cameras, interchangeable lenses, lens modules and microlenses. Hoya now has over 100 subsidiaries and affiliates, and employs approximately 38,000 people worldwide.

Contact Information:

Akiko Maeyama / Naoji Ito

Corporate Communications

Hoya Group

Tel: +81-3-3232-0065

E-mail: HOYA-pr@mb.hoya.co.jp


'/>"/>
SOURCE Hoya Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen Announces Third Quarter 2008 Financial Results
2. ScienceBased Health Announces the Launch of Diavis(TM), a New Dietary Supplement for the 81 Million Americans With or at Risk for Diabetes
3. Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc.
4. WellSpring Pharmaceutical Corp. Announces Hire of Wayne Miller as Vice President, Sales & Marketing, Consumer Brands
5. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
6. BIO-key(R) Announces Third Quarter 2008 Earnings Release and Conference Call Schedule
7. BioMS Medical Announces Third Quarter 2008 Results
8. Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
9. deCODE genetics Announces Third Quarter 2008 Financial Results
10. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
11. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... CA (PRWEB) , ... February 04, 2016 , ... ... enterprise talent development and compliance training, today announced an interactive FDA compliance ... Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific ... LC-MS, host live demos and poster sessions, and present on the analysis of ... takes place March 6 to 10 at the Georgia World Congress Center in ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
Breaking Biology Technology:
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
Breaking Biology News(10 mins):